ClassID:

108835

C12N7/04 - CPC Classification

Classification description:

Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof Inactivation or attenuation; Producing viral sub-units

Sub-classes:
Recent Application in this class:
#1
20260130983
2026-05-14

STABILIZATION OF VIRUS-BASED THERAPEUTIC AGENT

#2
20260097108
2026-04-09

POLYNUCLEOTIDES AND LENTIVIRAL VECTORS EXPRESSING NON-STRUCTURAL ANTIGENS OF A FLAVIVIRUS SELECTED FROM THE GROUP OF DENV, ZIKV AND YFV, INDUCING PROTECTIVE CD8+ T-CELL IMMUNITY IN A HOST

#3
20260078353
2026-03-19

Mammalian Cell Line for the Production of Modified Vaccinia Virus Ankara (MVA)

#4
20260077026
2026-03-19

METHODS FOR TREATING CANCER WITH HYPERACTIVE ADAR ENZYMES

#5
20260048114
2026-02-19

INFLUENZA VIRUS VACCINATION REGIMENS

#6
20250339512
2025-11-06

SELF-CLEAVING POLYPROTEINS AND USES THEREOF

#7
20250297286
2025-09-25

METHODS AND COMPOSITIONS FOR THE PRODUCTION OF RECOMBINANT ADENO-ASSOCIATED VIRUS (rAAV) VECTORS

#8
20250283055
2025-09-11

BROAD SPECTRUM VIRUS-TRAPPING NANOSHELLS

#9
20250161383
2025-05-22

VIRAL GENE THERAPY AS TREATMENT FOR CHOLESTEROL STORAGE DISEASE OR DISORDER

#10
20240417431
2024-12-19

VACCINE CANDIDATES FOR HUMAN RESPIRATORY SYNCYTIAL VIRUS (RSV) HAVING ATTENUATED PHENOTYPES

#11
20240352442
2024-10-24

METHOD FOR ATTENUATING INFLUENZA VIRUS BY SYNONYMOUS MUTATION AND DELETION MUTATION, AND ATTENUATED INFLUENZA VIRUS STRAIN AND USE

#12
20240342264
2024-10-17

VECTOR PRODUCTION

#13
20240316177
2024-09-26

IRRADIATION-INACTIVATED POLIOVIRUS, COMPOSITIONS INCLUDING THE SAME, AND METHODS OF PREPARATION

#14
20240042004
2024-02-08

Attenuated Virus of Flavivirus Virus and Use Thereof

#15
20240024459
2024-01-25

METHOD FOR PRODUCING AN ANTIGEN CORRESPONDING TO THE INACTIVATED SARS-COV-2 VIRUS, ANTIGEN CORRESPONDING TO THE INACTIVATED SARS-COV-2 VIRUS, ANTIGENIC COMPOSITION, KITS, AND USES THEREOF

#16
20230287083
2023-09-14

CD1 PEPTIDE-EPITOPE FOR USE IN THE TREATMENT OF A DISEASE CAUSED BY AN INTRACELLULAR PATHOGEN

#17
20230257719
2023-08-17

Production of High Titer Recombinant Vesicular Stomatitis Virus in Suspension Cell Culture

#18
20230089695
2023-03-23

COMPOSITIONS IMMUNOGENIC AGAINST SARS CORONAVIRUS 2, METHODS OF MAKING, AND USING THEREOF

#19
20220340619
2022-10-27

Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes

#20
20220193217
2022-06-23

Genomic deletion in African swine fever vaccine allowing efficient growth in stable cell lines

#21
20220047692
2022-02-17

Live-attenuated yellow fever virus strain adapted to grow on Vero cells and vaccine composition comprising the same

#22
20220010287
2022-01-13

Attenuated virus mutated at sites of evolutionarily conserved RNA structure

#23
20210407626
2021-12-30

Computational reduction vaccine for Covid-19 Bin75

#24
20210346489
2021-11-11

Vector production

#25
20210338808
2021-11-04

THERAPEUTIC VACCINE FOR THE TREATMENT OF PAPILLOMAVIRUS LESIONS

#26
20210205366
2021-07-08

METHOD FOR ACTIVATING IMMUNOCYTES IN VITRO

#27
20210198636
2021-07-01

Use of Syncytin for Targeting Drug and Gene Delivery to Lung Tissue

#28
20210188920
2021-06-24

Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes

#29
20210177960
2021-06-17

Recombinant respiratory syncytial virus strains comprising NS1 and NS2 gene shifts

#30
20210161979
2021-06-03

CHIMERIC VSV VIRUS COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATMENT OF CANCER

#31
20210154289
2021-05-27

Live-attenuated yellow fever virus strain adapted to grow on Vero cells and vaccine composition comprising the same

#32
20210145907
2021-05-20

Zika virus strains for treatment of glioma

#33
20210128713
2021-05-06

Irradiation-inactivated poliovirus, compositions including the same, and methods of preparation

#34
20210113635
2021-04-22

Viral gene therapy as treatment for cholesterol storage disease or disorder

#35
20210106675
2021-04-15

Therapeutic vaccine for the treatment of papillomavirus lesions

#36
20200316190
2020-10-08

Method of inhibiting enveloped virus binding to target cells by incorporating P-selectin glycoprotein ligand-1 (PSGL-1) into virions

#37
20200270584
2020-08-27

METHOD FOR RAPID GENERATION OF AN ATTENUATED RNA VIRUS

#38
20200208173
2020-07-02

ADENOVIRUS CONTROL VIRUS

#39
20200181581
2020-06-11

Compositions featuring an attenuated newcastle disease virus and methods of use for treating neoplasia

#40
20200101182
2020-04-02

METHODS FOR INACTIVATING, ON MEDICAL INSTRUMENTS AND DEVICES, VIRUSES CONTAINING RNA AND DNA, AND APPARATUSES FOR IMPLEMENTATING SAME

#41
20200085939
2020-03-19

Attenuated mutant dengue viruses comprising a mutation in the NS5 non-structural protein

#42
20190345454
2019-11-14

ROTAVIRUS-LIKE PARTICLE PRODUCTION IN PLANTS

#43
20190275139
2019-09-12

Temperature-sensitive attenuated FMDV strains, construction method and application thereof

#44
20190247494
2019-08-15

Polypeptide carrier for presenting target polypeptide and uses thereof

#45
20190247486
2019-08-15

Chimeric norovirus P particle and preparation and use thereof

#46
20190240314
2019-08-08

Purification of recombinant EV71 virus-like particle and method for preparing vaccine thereof

#47
20190233476
2019-08-01

Vaccine candidates for human respiratory syncytial virus (RSV) having attenuated phenotypes

#48
20190211313
2019-07-11

Compositions and methods for generating reversion free attenuated and/or replication incompetent vaccine vectors

#49
20190184000
2019-06-20

Recombinant respiratory syncytial virus strains comprising NS1 and NS2 gene shifts

#50
20190144836
2019-05-16

Duck enteritis virus and the uses thereof

#51
20190144835
2019-05-16

Duck enteritis virus and the uses thereof

#52
20190136209
2019-05-09

Duck enteritis virus and the uses thereof

#53
20190136208
2019-05-09

Duck Enteritis Virus and the uses thereof

#54
20190117711
2019-04-25

Chimeric VSV virus compositions and methods of use thereof for treatment of cancer

#55
20190002837
2019-01-03

Attenuated virus having multiple hosts

#56
20180371026
2018-12-27

Feline calicivirus vaccine

#57
20180344837
2018-12-06

Viable viruses with foreign tags

#58
20180273911
2018-09-27

Attenuated virus mutated at sites of evolutionarily conserved RNA structure

#59
20180255751
2018-09-13

Delivery, use and therapeutic applications of the CRISPR-cas systems and compositions for modeling mutations in leukocytes

#60
20180243399
2018-08-30

FCV recombinant vaccines and uses thereof

#61
20180208904
2018-07-26

Host regulatory factor that enhances replication and/or propagation of vaccinia virus

#62
20180201908
2018-07-19

Method for rapid generation of an attenuated RNA virus

#63
20180195085
2018-07-12

IMPROVED NEGATIVE-STRAND RNA VIRAL VECTOR

#64
20180187164
2018-07-05

Duck enteritis virus and the uses thereof

#65
20180133310
2018-05-17

Methods and compositions for treating herpes

#66
20180119158
2018-05-03

Modified CPMV enhancer elements

#67
20180104289
2018-04-19

VIRAL GENE THERAPY AS TREATMENT FOR CHOLESTEROL STORAGE DISEASE OR DISORDER

#68
20180079786
2018-03-22

Constructs for continuous monitoring of live cells

#69
20180016561
2018-01-18

Rotavirus-like particle production in plants

#70
20180008696
2018-01-11

Influenza virus vaccination regimens

#71
20180002384
2018-01-04

JC polyomavirus VLP (virus-like particle) with a targeting peptide

#72
20180000925
2018-01-04

Viral RNA segments as immunomodulatory agents and vaccine components

#73
20170362578
2017-12-21

Method for preparing a vaccine antigen, resulting vaccine antigen and uses

#74
20170350889
2017-12-07

Cell identification method

#75
20170298389
2017-10-19

HSV VACCINES

#76
20170166612
2017-06-15

Method for enhancing immunogenicity of epitope peptide of HPV antigen, virus-like particle, and method for preparing HPV vaccine

#77
20170165348
2017-06-15

Vector production

#78
20170112922
2017-04-27

Attenuated recombinant vesicular stomatitis virus vaccine vectors comprising modified matrix proteins

#79
20170056538
2017-03-02

Methods for inactivating, on medical instruments and devices, viruses containing RNA and DNA, and apparatuses for implementating same

#80
20160317650
2016-11-03

Gene-deleted variant strain of porcine pseudorabies virus, vaccine composition, method of making the same and use thereof

#81
20160296572
2016-10-13

Chimeric VSV virus compositions and methods of use thereof for treatment of cancer

#82
20160281065
2016-09-29

Gene-deleted variant strain of porcine pseudorabies virus, vaccine composition, method of making the same and use thereof

#83
20160208222
2016-07-21

Compositions featuring an attenuated Newcastle disease virus and methods of use for treating neoplasia

#84
20160158342
2016-06-09

Vaccines for diseases caused by viruses of the family of reoviridae

#85
20160136261
2016-05-19

Live attenuated vaccines for influenza viruses

#86
20160136260
2016-05-19

Attenuated influenza vaccines and uses thereof

#87
20160120973
2016-05-05

Attenuated swine influenza vaccines and methods of making and use thereof

#88
20160114029
2016-04-28

Porcine pseudorabies virus, vaccine composition and preparation method and use thereof

#89
20150252334
2015-09-10

Method for in-vitro preparation of double-layered virus-like particles of rotavirus

#90
20150209422
2015-07-30

Immunization with rabies virus vector expressing foreign protein antigen

#91
20150086577
2015-03-26

Pathogenic phlebovirus isolates and compositions and methods of use

#92
20140302593
2014-10-09

Process for purifying VLPs

#93
20140186395
2014-07-03

PERMISSIVE CELLS AND USES THEREOF

#94
20140127261
2014-05-08

Flavivirus envelope protein mutations affecting virion disassembly

#95
20140107207
2014-04-17

Method for inactivating viruses with slightly acidic arginine

#96
20140023681
2014-01-23

Attenuated swine influenza vaccines and methods of making and use thereof

#97
20130243729
2013-09-19

Anti-cancer adenoviruses

#98
20130171150
2013-07-04

FELINE PICORNA VIRUS AND USES THEREOF

#99
20120114694
2012-05-10

Recombinant attenuated dengue viruses comprising mutations in NS5 and the 3′ untranslated region

#100
20120034267
2012-02-09

INACTIVATED VARICELLA ZOSTER VIRUS VACCINES, METHODS OF PRODUCTION, AND USES THEREOF

#101
20100158947
2010-06-24

Permissive cells and uses thereof

#102
20100107264
2010-04-29

Development of influenza A antivirals

#103
20090263424
2009-10-22

Recombinant attenuated dengue viruses comprising a deletion in the 3′ untranslated region and additional attenuating mutations induced by chemical mutagenesis

#104
20080318300
2008-12-25

Method for inactivating viruses with slightly acidic arginine

#105
20070249033
2007-10-25

Methods of terminal sterilization of biological products

#106
20070160982
2007-07-12

Development of influenza A antivirals

#107
20070092534
2007-04-26

Attenuated dengue virus comprising mutations in the NS3 gene

#108
20060177909
2006-08-10

Preparation of immunoglobulin

#109
20050010043
2005-01-13

Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses